Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New UK Biotech MiroBio Raises $34m For Autoimmune Disease Research

Executive Summary

Company is keeping its cards close to chest on exact mechanism as it enters increasingly competitive autoimmune disease field.

You may also be interested in...



Gilead Grabs MiroBio's Checkpoint Agonists For $405m

Just over a month after raising $97m in a series B round, Oxford University spinout MiroBio and its immune checkpoint agonists have been snapped up by Gilead Sciences. 

Ex-Novartis Exec Joins Checkpoint Agonist-Focused Biotech

The Oxford university spin-out MiroBio has a senior leadership team in place, and aims to have its first checkpoint agonists in the clinic in 2022. Scrip spoke to its CEO about its plans.

Finance Watch: 3Q Biopharma Venture Capital Financings Fell From 2Q Spike

VC deals totaled $8.3bn in the first half of 2019, but the year's total rose to just $11.5bn at the end of September, reflecting only a $3.2bn third quarter gain. Among recent financings, Cygnal emerged from stealth mode with $65m invested to date.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC125982

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel